An industry commentary argues that the strategic value of medicines can change as treatment paradigms, coverage, and technology evolve—using chronic obesity therapies as the clearest example. It revisits a timeline starting with an FDA-approved oral weight-management combination in 2014, the market’s rapid uptake after the product became the most-prescribed branded option, and a later Chapter 11 filing by the manufacturer. The piece argues that the GLP-1 era altered not only pharmacology expectations but also physician engagement and payer access to obesity care—meaning underperformance may reflect mismatched context as much as molecule limits. For biotech leaders, the core message is a decision framework: established drugs that struggled may warrant re-analysis when today’s market infrastructure and patient behavior provide a different path to value than when the asset was launched.